A detailed history of Two Sigma Investments, LP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 358,064 shares of BDTX stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
358,064
Previous 367,293 2.51%
Holding current value
$1.71 Million
Previous $1.03 Million 75.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.67 - $5.74 $24,641 - $52,974
-9,229 Reduced 2.51%
358,064 $1.82 Million
Q4 2023

Feb 14, 2024

BUY
$1.77 - $3.03 $508,289 - $870,122
287,169 Added 358.41%
367,293 $1.03 Million
Q3 2023

Nov 14, 2023

BUY
$2.87 - $4.99 $229,955 - $399,818
80,124 New
80,124 $229,000
Q1 2023

May 15, 2023

SELL
$1.35 - $3.14 $48,478 - $112,757
-35,910 Reduced 25.0%
107,754 $203,000
Q4 2022

Feb 14, 2023

SELL
$1.28 - $2.51 $82,213 - $161,214
-64,229 Reduced 30.9%
143,664 $258,000
Q3 2022

Nov 14, 2022

SELL
$1.96 - $4.01 $103,078 - $210,889
-52,591 Reduced 20.19%
207,893 $351,000
Q2 2022

Aug 15, 2022

SELL
$1.5 - $3.63 $220,408 - $533,388
-146,939 Reduced 36.07%
260,484 $641,000
Q1 2022

May 16, 2022

BUY
$2.66 - $5.61 $283,079 - $597,021
106,421 Added 35.36%
407,423 $1.13 Million
Q4 2021

Feb 14, 2022

BUY
$5.18 - $8.48 $21,735 - $35,582
4,196 Added 1.41%
301,002 $1.6 Million
Q3 2021

Nov 15, 2021

SELL
$8.46 - $12.42 $993,043 - $1.46 Million
-117,381 Reduced 28.34%
296,806 $2.51 Million
Q2 2021

Aug 16, 2021

BUY
$12.19 - $28.17 $3.55 Million - $8.21 Million
291,421 Added 237.38%
414,187 $5.05 Million
Q1 2021

May 17, 2021

SELL
$22.23 - $34.75 $75,004 - $117,246
-3,374 Reduced 2.67%
122,766 $2.98 Million
Q4 2020

Feb 16, 2021

BUY
$29.47 - $35.0 $3.72 Million - $4.41 Million
126,140 New
126,140 $4.04 Million

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $174M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.